KDR and non-small cell lung carcinoma: Anlotinib is a new orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit, approved by China Food and Drug Administration (CFDA) in 2018 as third-line treatment for advanced NSCLC on the bases of the ALTER 0303 study (40).